Precision Medicine Software Genedata Profiler Launched at Bio-IT World

Open, interoperable enterprise platform for patient and compound profiling provides important data management infrastructure for pharma internal R&D processes. Cuts time & costs in translational research projects by efficiently processing, managing and analyzing NGS and other omics data; facilitates data, method and result sharing across entire organization; ensures data privacy and data security.

Boston, MA, USA, April 21, 2015

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced at Bio-IT World Conference & Expo ’15 the launch of Genedata ProfilerTM, an open, interoperable enterprise software platform designed to facilitate efficient patient and compound profiling processes. Efficient profiling processes are a crucial element of successful precision medicine approaches in (bio-) pharmaceutical R&D. One particular strength of Genedata Profiler™ is that it supports the integrative analysis of NGS and other omics data with clinical patient data, ensuring the highest data security and quality standards.

The US National Institutes of Health defines precision medicine as “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.” Genedata Profiler was developed in collaboration with leading pharmaceutical companies to process, manage and analyze very large data sets that include this genomic and phenotypic information. It delivers insight for pharmaceutical R&D to improve preclinical and clinical studies. In particular, Genedata Profiler manages and federates all omics and related data from clinical samples while maintaining full patient privacy and chain of custody. Working with disease and genomic information from different studies, it allows innovative integrative data analyses. The software enables easy data, method and result sharing, promoting interdisciplinary collaboration between research teams both within and outside the organization.

Dr. Othmar Pfannes, CEO of Genedata, commented: “Today’s launch of Genedata Profiler is another milestone in our strategy to deliver innovative solutions for efficient drug discovery and development processes. We believe successful precision medicine and translational research requires great efficiency in working with data from human samples in research environments. Interdisciplinary teams working on and distributing data must be able to collaborate easily, and should also be able to integrate disease and genomic information from external studies into their analyses.  Our experience and domain knowledge, coupled with our collaborative approach with leading pharmaceutical companies worldwide, allow Genedata to provide solutions to all of these challenges in one complete software package.”

Genedata Profiler is available immediately for annual licensing. The software will be demonstrated at Booth 232 in the Bio-IT World Expo in Seaport World Trade Center in Boston, April 21–23, 2015.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.
Follow Us on LinkedIn

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.